https://www.bioworld.com/rss en-us Wuhan Createrna Science and Technology Co. Ltd. has synthesized new cyclobutenedione compounds acting as C-C chemokine receptor type 6 (CCR6) antagonists potentially useful for the treatment of inflammatory bowel disease, allergy, dry eye, psoriasis, rheumatoid arthritis and multiple sclerosis. http://www.bioworld.com/articles/731970 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731970-ccr6-antagonists-disclosed-in-wuhan-createrna-patent Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant colony-stimulating factor 1 receptor inhibitor, with plans to move the asset into a biomarker-based and placebo-controlled study. http://www.bioworld.com/articles/731877 Mon, 15 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731877-elixirons-enrupatinib-shows-upbeat-interim-phase-ii-ad-results Illustration of amyloid plaques in Alzheimer's disease More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways involving complement factor 5 and its receptor (C5aR1) were overexpressed, and that a C5aR1 antagonist, avacopan, reduced the need for glucocorticoids and improved renal recovery. This led researchers to investigate the association of anti-C5aR1 antibodies with GCA and its outcomes. http://www.bioworld.com/articles/731857 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731857-anti-c5ar1-antibodies-linked-to-outcomes-in-giant-cell-arteritis Medical illustration showing layers of a blood vessel CD45RC is an isoform of protein tyrosine phosphatase receptor type C, a protein that plays a key role in regulating antigen receptor signaling in T and B cells. While it is expressed on most circulating B cells, it is only highly expressed on Th1 precursors, Th1 cells and T effector memory CD45RA+ cells (TEMRA). http://www.bioworld.com/articles/731838 Thu, 11 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731838-cd45rc-identified-as-therapeutic-target-in-sjogren-disease Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by competitor Sanofi SA, which said that the phase III Mobilize study testing riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) will be stopped for futility. http://www.bioworld.com/articles/731720 Wed, 10 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731720-sanofi-phase-iii-cidp-quit-dents-dianthus-c1-mismatch 3D illustration of a nerve cell Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said. http://www.bioworld.com/articles/731828 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731828-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios Deal handshake with coin, chart background CD39, also known as ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1), is a cell surface ectonucleotidase with key roles in modulating inflammation and localized immune regulation. Researchers from the Baker Heart and Diabetes Institute and collaborators recently proposed leveraging mRNA technologies to provide sustained, localized CD39 expression without genomic integration. http://www.bioworld.com/articles/731738 Mon, 08 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731738-cd39-mrna-loaded-nanoliposomes-attenuate-local-acute-inflammation Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said. http://www.bioworld.com/articles/731632 Fri, 05 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731632-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios Deal handshake with coin, chart background Genome-wide association studies (GWAS) have identified multiple loci associated with complex diseases, but these are mostly on regulatory genes in the non-coding part of the genome and it has proved difficult to identify the effector genes that they control. Now, researchers in the U.K. have shown how single cell sequencing at scale can be used to precisely link non-coding GWAS loci to specific protein coding genes and cell types. http://www.bioworld.com/articles/731755 Fri, 05 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731755-technique-links-non-coding-mutations-to-disease-genes-they-regulate Gastrointestinal system with DNA, scientific background Genome-wide association studies (GWAS) have identified multiple loci associated with complex diseases, but these are mostly on regulatory genes in the non-coding part of the genome and it has proved difficult to identify the effector genes that they control. Now, researchers in the U.K. have shown how single cell sequencing at scale can be used to precisely link non-coding GWAS loci to specific protein coding genes and cell types. http://www.bioworld.com/articles/731544 Wed, 03 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731544-technique-links-non-coding-mutations-to-disease-genes-they-regulate Gastrointestinal system with DNA, scientific background Adipose triglyceride lipase (ATGL), a central mediator of triglyceride hydrolysis and fatty acid mobilization, modulates hepatic lipid homeostasis and metabolic signaling pathways that contribute to the activation of fibrogenic responses. http://www.bioworld.com/articles/731598 Wed, 03 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731598-atgl-inhibition-reshapes-immunometabolism-in-liver-fibrosis Doctor pointing at liver China Pharmaceutical University and the Chongqing Innovation Institute, China Pharmaceutical University have synthesized new asiaticoside saponin compounds reported to be useful for the treatment of inflammation, cancer and ulcerative colitis. http://www.bioworld.com/articles/731590 Tue, 02 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731590-china-pharmaceutical-university-discloses-new-asiaticoside-saponin-compounds Army Medical University has identified new cyclic GMP-AMP synthase (MB21D1; cGAS)/STING pathway inhibitors potentially useful for the treatment of inflammatory disorders. http://www.bioworld.com/articles/731570 Mon, 01 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731570-army-medical-university-reports-new-cgas-sting-pathway-inhibitors Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that autoimmunity might underlie the persistent neurological symptoms seen in long COVID, researchers at Yale University and Mount Sinai now reinforce this hypothesis. SARS-CoV-2 infection appears to trigger an autoimmune mechanism that drives chronic pain, fatigue and cognitive impairment in some patients. http://www.bioworld.com/articles/731473 Thu, 28 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731473-new-evidence-links-autoimmunity-to-long-covid-symptoms Illustration of antibodies and viral infection Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases. http://www.bioworld.com/articles/731235 Thu, 21 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731235-recludix-presents-stat1-3-inhibitors-for-dermatological-diseases Skin irritation on hands Beijing Tide Pharmaceutical Co. Ltd. has divulged new salts of known angiotensin AT2 recpetor antagonists potentially useful for the treatment of allergy, autoimmune and demyelinating diseases, cerebrovascular, respiratory, cognitive, gastrointestinal and inflammatory disorders, among others. http://www.bioworld.com/articles/731189 Wed, 20 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731189-beijing-tide-pharmaceutical-synthesizes-new-angiotensin-at2-antagonists Neurolambda Therapeutics Inc. has disclosed new non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of cancer, systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis. http://www.bioworld.com/articles/731149 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731149-neurolambda-therapeutics-patents-new-tyk2-inhibitors Researchers from the University of Copenhagen and collaborating institutions aimed to develop a therapy for chronic neuropathic pain based on gene therapy delivered with adeno-associated viral (AAV) vectors. http://www.bioworld.com/articles/731138 Mon, 18 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731138-aav-encoded-dimeric-pick1-inhibitors-reduce-inflammatory-neuropathic-pain-in-mice Korean researchers reported the discovery and preclinical characterization of KSI-028, a novel tetrahydroquinoline-based STING inhibitor with activity across multiple models of STING activation. http://www.bioworld.com/articles/731120 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731120-ksi-028-suppresses-sting-driven-inflammation Aeovian Pharmaceuticals Inc. has divulged new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma, vascular disorders, Duchenne muscular dystrophy, liver and metabolic diseases, among others. http://www.bioworld.com/articles/731086 Wed, 13 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731086-aeovian-pharmaceuticals-synthesizes-new-cd38-inhibitors Boehringer Ingelheim Pharma GmbH & Co. KG and Immunitas Therapeutics Inc. have signed a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases. http://www.bioworld.com/articles/731077 Wed, 13 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731077-boehringer-ingelheim-licenses-immunitas-antibody-program 3D illustration antibody AOP Orphan Pharmaceuticals GmbH (AOP Health) has established a strategic partnership with VRG Therapeutics Zrt to advance a novel Kv1.3 potassium channel inhibitor for use in inflammation and immunology indications. http://www.bioworld.com/articles/731074 Wed, 13 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731074-aop-health-and-vrg-therapeutics-partner-on-immunology-program Scientist, microscope and dropper Raising $279 million in an IPO and another $25 million in a concurrent private placement, Odyssey Therapeutics Inc. is advancing its lead phase II asset, OD-001, in ulcerative colitis, with plans to bring its SLC15A4 program into the clinic for lupus. http://www.bioworld.com/articles/730980 Fri, 08 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730980-odysseys-ipo-placement-brings-304m-to-lead-drugs-in-ibd-lupus IPO, coins, financial chart Avalo Therapeutics Inc. may have designed in lead asset abdakibart, a drug for hidradenitis suppurativa (HS) that offers a novel mechanism of action, wide dosing interval, and more-than-satisfying outcomes on the Hidradenitis Suppurativa Clinical Response 75 endpoint, just what the doctor – and Wall Street – ordered. http://www.bioworld.com/articles/730861 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730861-abdakibart-phase-ii-graded-puts-avalo-in-hs-upper-class Hand held near armpit A team at the Korea Research Institute of Chemical Technology has synthesized tetrahydroisoquinoline- or isoindoline-substituted [1,2,4]triazolo[1,5-a]pyridine derivatives acting as tyrosine-protein kinase JAK1 inhibitors. a]pyridine derivatives acting as tyrosine-protein kinase JAK1 inhibitors.]]> http://www.bioworld.com/articles/730915 Wed, 06 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730915-korea-research-institute-of-chemical-technology-reports-new-jak1-inhibitors The classic origin story for a biotech startup is that of a scientist who nurtures his work out of a university and to commercial success. For Link Biologics Ltd. and its TSG6-based pipeline, the story is the other way around; it began with now-CEO Reuben Dawkins meeting University of Manchester scientists Tony Day and Caroline Milner while he was on the lookout for “great science that needs help to make it to patients.” The three are now co-founders of Link, which spun out of the University of Manchester in 2021 and has four programs in three indications, all based on TSG-6 biology. http://www.bioworld.com/articles/730902 Wed, 06 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730902-eyes-are-first-prize-for-newco-link-biologics Rays of light beaming from eye Evotec SE has announced the nomination of a small-molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall SA. The program is aimed at developing novel treatments for immune-mediated inflammatory skin diseases with high unmet medical need. The collaboration, established in 2022, leverages Evotec’s fully integrated, AI/machine learning enhanced discovery and preclinical development platforms. http://www.bioworld.com/articles/730882 Tue, 05 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730882-evotec-and-almirall-derm-alliance-yields-development-candidate Illustration showing skin anatomy Ono Pharmaceutical Co. Ltd. has synthesized bridged bicyclic compounds acting as endosomal/lysosomal proton channel TMEM175 activators. As such, they are described as potentially useful for the treatment of inflammatory disorders, lysosomal storage diseases, autoimmune disease and Parkinson’s disease. http://www.bioworld.com/articles/730805 Thu, 30 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730805-tmem175-activators-reported-in-ono-pharmaceutical-patent Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has recently presented data for their AhR agonist EQ-504 for the potential treatment of immune-related diseases. http://www.bioworld.com/articles/730794 Thu, 30 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730794-eq-504-is-ahr-agonist-for-ulcerative-colitis-related-disorders A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome proliferator activated receptors (PPAR α/γ/δ). GLP-1-GIP-Lani enables targeted delivery of the PPAR agonist to cells that express incretin receptors, enhancing weight loss, improving glucose control and reducing inflammation in obese mice. In these models, it surpassed the effects of GLP-1 receptor agonists such as semaglutide and GLP-1-GIP co-agonists such as tirzepatide in reducing body weight, improving glycemic control and enhancing metabolic outcomes during active treatment. http://www.bioworld.com/articles/730790 Thu, 30 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730790-quintuple-glp-1gipppar-agonist-for-obesity-and-diabetes-control Glucagon-like peptide-1 receptor (GLP-1R) complex Glucagon-like peptide-1 receptor (GLP-1R) complex, representing the molecular target for GLP-1 agonists. Detailed view of the binding site with small-molecule agonist.